Boston University

bu.edu

Total trials

414

Active

88

Phase 3

11

Total enrollment

9,700,869

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 15 of 15 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Ibuprofen1
Acetominophen1
Combination cream of 5-fluorouracil and calcipotriene1
5-fluorouracil cream1
Levofloxacin3
Delamanid2
Linezolid2
Allopregnanolone (Allo) with Dexolve in 0.9% saline for injection manufactured by University of California, Davis1
Bedaquiline1
Clofazimine1
Vitamin K1 500 µg1
K1 1000 µg1
Vitamin K2 (MK-7) 300 µg1
Pramlintide challenge test1
Sertraline1

Next readouts

  • 2026-11
  • 2026-12
  • 2026-12
  • 2027-03
  • 2027-04-01
  • 2027-05
  • 2027-06

Top conditions

  • HIV24
  • Depression14
  • Parkinson Disease9
  • HIV Infections9
  • Cardiovascular Diseases9
  • Stroke8
  • Anxiety8
  • Vitamin D Deficiency8

Frequently asked questions about Boston University

How many clinical trials does Boston University have on ClinicalTrials.gov?
Boston University is listed as the lead sponsor on 414 clinical trials in ClinicalTrials.gov, 88 of which are currently active (recruiting, enrolling, or ongoing).
How many of Boston University's trials are in Phase 3?
11 of Boston University's trials are in Phase 3, spread across 15 active drug programs.
What therapeutic areas does Boston University focus on?
Boston University's most-studied conditions on ClinicalTrials.gov are HIV, Depression, Parkinson Disease, HIV Infections, Cardiovascular Diseases.
When are Boston University's next clinical trial readouts?
Boston University has 7 upcoming primary-completion readouts tracked here; the soonest is “Multi-Center Development of a Novel Diagnostic Test for Alzheimer's Disease”, expected around 2026-11.